|
Market Closed -
Nasdaq
01:00:00 13/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 47.15 USD | -4.48% |
|
-17.94% | -28.98% |
| 04:00am | Arrowhead Pharmaceuticals, Inc., 2026 Earnings Call, Nov 12, 2026 | |
| 11-13 | Arrowhead Pharmaceuticals FY Loss Widens, Revenue Falls | MT |
| Market Cap | 6.66B 6.02B 5.56B 5.03B 9.5B 626B 9.78B 66.73B 26.52B 335B 25B 24.46B 1,065B | P/E 2027 * |
-10.1x | P/E 2028 * | -19.6x |
|---|---|---|---|---|---|
| Enterprise Value | 5.98B 5.41B 4.99B 4.52B 8.52B 562B 8.78B 59.89B 23.8B 300B 22.43B 21.96B 956B | EV / Sales 2027 * |
17.5x | EV / Sales 2028 * | 9.85x |
| Free-Float |
94.56% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ARWR | Delayed | |
CBOE
| ARWR | Real-time | |
|
Berne S.E.
| HDP1 | End-of-day quote | |
|
Tradegate
| HDP1 | Real-time | |
|
London S.E.
| 0HI3 | Delayed | |
|
Deutsche Boerse AG
| HDP1 | Delayed | |
|
Börse Stuttgart
| HDP1 | Delayed | |
|
Boerse Muenchen
| HDP1 | Real-time | |
|
Xetra
| HDP1 | Delayed |
Last Transcript: Arrowhead Pharmaceuticals, Inc.
| 1 day | -4.48% | ||
| 1 week | -17.94% | ||
| Current month | -21.29% | ||
| 1 month | -22.36% | ||
| 3 months | -45.96% | ||
| 6 months | -40.35% | ||
| Current year | -28.98% |
| 1 week | 46.45 |  | 53.62 |
| 1 month | 46.45 | | 62 |
| Current year | 46.45 | | 95.49 |
| 1 year | 37.06 | | 95.49 |
| 3 years | 9.57 | | 95.49 |
| 5 years | 9.57 | | 95.49 |
| 10 years | 1.2 | | 95.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/12/2007 | |
Daniel Apel
DFI | Director of Finance/CFO | - | 13/05/2025 |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | - | |
Mauro Ferrari
BRD | Director/Board Member | 66 | 19/08/2010 |
Michael Perry
BRD | Director/Board Member | 66 | 19/12/2011 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/08/26 | Sell | Director | -2,000 | 0.0014% | ||
| 18/08/26 | Sell | Director | -11,600 | 0.0082% | ||
| 15/06/26 | Free | Director | 11,882 | 0.0084% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.48% | -17.94% | +13.83% | +74.89% | 6.66B | |
| +1.10% | -2.67% | +62.79% | +70.47% | 68.45B | |
| -0.05% | +8.63% | +15.27% | +92.61% | 61.31B | |
| -0.45% | +0.03% | +20.09% | +97.74% | 55.73B | |
| -0.96% | +7.41% | +10.20% | +108.91% | 47.51B | |
| -1.25% | +2.35% | +22.74% | +38.34% | 44.68B | |
| -2.41% | -0.73% | +167.89% | +794.72% | 38.14B | |
| +1.21% | -2.56% | +20.27% | +52.81% | 35.85B | |
| -1.52% | -1.62% | +76.64% | +53.68% | 33.05B | |
| -2.22% | +8.56% | -39.26% | +397.14% | 25.9B | |
| Average | -1.10% | +0.61% | +37.05% | +178.13% | 42B | |
| Weighted average by Cap. | -0.58% | +2.51% | +39.76% | +162.00% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 341M 309M 285M 258M 487M 32.08B 501M 3.42B 1.36B 17.15B 1.28B 1.25B 54.6B | 628M 568M 524M 475M 896M 59.07B 923M 6.3B 2.5B 31.58B 2.36B 2.31B 101B |
| Net income | -652M -590M -545M -493M -930M -61.33B -958M -6.54B -2.6B -32.79B -2.45B -2.4B -104B | -351M -317M -293M -265M -500M -33B -515M -3.52B -1.4B -17.64B -1.32B -1.29B -56.15B |
| Net Debt | -683M -617M -570M -516M -973M -64.19B -1B -6.84B -2.72B -34.32B -2.56B -2.51B -109B | -473M -427M -395M -357M -674M -44.43B -694M -4.74B -1.88B -23.75B -1.77B -1.74B -75.61B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/11/26 | $47.15 | -4.48% | 2,164,345 |
| 11/11/26 | $49.36 | +0.73% | 2,529,478 |
| 10/11/26 | $49.00 | -0.49% | 2,637,109 |
| 09/11/26 | $49.24 | -15.34% | 8,055,056 |
| 06/11/26 | $58.16 | +1.22% | 1,363,197 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ARWR Stock
Select your edition
All financial news and data tailored to specific country editions
